Spotlight on idarucizumab and its potential for the reversal of anticoagulant effects of dabigatran [PDF]
Drug Design, Development and Therapy, 2016 Pierre Sié Hematology Laboratory, Academic Hospital of Toulouse, Hospital Rangueil, Toulouse, France Abstract: Idarucizumab is the first targeted antidote of dabigatran, a direct oral anticoagulant used for prevention and treatment of venous ...
Pierre Sie
exaly +3 more sources
The new way of Dabigatran reversal – Idarucizumab [PDF]
Journal of Education, Health and Sport, 2019 Since last few years a popularity of new oral anticoagulants significantly raised. There are following main direct oral anticoagulants (DOAC) used in therapy: Dabigatran, Rywaroxaban, Apixaban, Endoxaban.
Erwin Ciechański +3 more
doaj +7 more sources
Кардиоваскулярная терапия и профилактика, 2023 The number of patients with indications for direct oral anticoagulants (DOACs) to prevent thrombotic events is steadily growing. However, in 1,1-2,2% of cases, ischemic strokes occur within DOAC therapy.
G. R. Ramazanov +6 more
doaj +2 more sources
Idarucizumab more effectively reverses the anticoagulant effects of dabigatran acylglucuronide than dabigatran [PDF]
Scientific ReportsDabigatran acylglucuronide, an active metabolite of dabigatran, exhibits higher plasma concentrations and distinct anticoagulant effects compared to dabigatran, suggesting that it may play a more significant role in overall anticoagulant activity than ...
Jong-Min Kim +4 more
doaj +2 more sources
Idarucizumab Reversal in Subdural Hemorrhage: A Single-Center Experience [PDF]
LifePrompt reversal of anticoagulation in the elderly population with subdural hematoma (SDH) is critical to reduce morbidity and facilitate timely surgical intervention. In patients receiving dabigatran, idarucizumab provides rapid anticoagulation reversal.
Anita Mrvar Brečko +5 more
doaj +2 more sources
Intravenous thrombolysis for acute cerebral embolism during atrial fibrillation ablation: a case report and systematic review with meta-analysis [PDF]
Frontiers in Cardiovascular MedicineIntroductionPeriprocedural stroke represents a clinically important complication of atrial fibrillation ablation, and effective anticoagulation remains essential for risk reduction.
Bin Cai +5 more
doaj +2 more sources
Bleeding Risk of Anticoagulation Reversal Strategies Before Heart Transplantation: A Retrospective Comparative Cohort Study [PDF]
Journal of Cardiovascular Development and DiseaseHeart transplantation (HT) poses high bleeding risks, especially for patients on anticoagulation. This study evaluates the use of idarucizumab for dabigatran (DBG) reversal compared to vitamin K antagonist (VKA) strategies in HT. A retrospective analysis
Antonio Prieto-Romero +10 more
doaj +2 more sources
Reversal of dabigatran and apixaban-induced coagulopathy using idarucizumab, fibrinogen, and prothrombin complex concentrate: A case report [PDF]
HeliyonThis case report examines the combined use of fibrinogen concentrate, four-factor prothrombin complex concentrate (PCC), and idarucizumab, a specific antidote for dabigatran, to reverse the anticoagulant effects of dabigatran and apixaban-induced ...
Elia Morando +6 more
doaj +2 more sources
Cost-effectiveness of dabigatran for thromboembolic events prevention in atrial fibrillation patients in Chile [PDF]
Cost Effectiveness and Resource AllocationBackground Atrial fibrillation (AF) is the most common sustained arrhythmia in adults, associated with significant morbidity, mortality, and economic burden due to thromboembolic events.
Tomás Abbot +5 more
doaj +2 more sources
Dabigatran accumulation in acute kidney injury: is more better than less to prevent bleeding? A case report [PDF]
International Journal of Emergency MedicineDabigatran is an oral anticoagulant that is mainly renally excreted. Despite its efficacy in preventing thromboembolic events, concerns arise regarding bleeding complications in patients with acute kidney injury. Idarucizumab is its specific antidote and
Rafik Matbouli +5 more
doaj +2 more sources